Group 1 - The company, Valiant Bio-B (09887.HK), plans to globally offer 32.0544 million H-shares, with 3.2055 million shares available in Hong Kong and 28.8489 million shares for international offering, with the offering period from July 17 to July 22, 2025, and expected pricing on July 23, 2025 [1] - The expected price range for the shares is HKD 31.60 to HKD 35.00 per share, with a trading unit of 100 shares, and Morgan Stanley and CITIC Securities are the joint sponsors [1] - The company was established in 2012 and focuses on discovering, developing, and commercializing new therapies for cancer, autoimmune diseases, and other major diseases, with one core product LBL-024 currently in the registration clinical stage [1] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling USD 69 million (approximately HKD 541.6 million) under certain conditions [2] - Assuming a mid-range offering price of HKD 33.30 per share, cornerstone investors are expected to subscribe for approximately 16.2645 million shares [2] - Key cornerstone investors include Tencent Holdings (00700.HK), Highfields Capital, and others [2] Group 3 - If the offering adjustment rights and over-allotment options are not exercised, and assuming a share price of HKD 33.30, the company estimates net proceeds from the global offering to be approximately HKD 967.7 million [3] - The estimated proceeds will be allocated as follows: approximately 65% for clinical development and regulatory affairs of clinical-stage candidates, 15% for enhancing preclinical assets and expanding the pipeline, 10% for increasing production capacity, and 10% for working capital and general corporate purposes [3] Group 4 - Valiant Bio-B is expected to be listed on July 25, 2025, with cornerstone investors such as Tencent and Highfields supporting the offering [4]
维立志博-B(09887.HK)预计7月25日上市 腾讯、高毅等基石投资者力捧